Download PDF
Thromb Haemost 2019; 119(07): 1171-1181
DOI: 10.1055/s-0039-1688789
Atherosclerosis and Ischaemic Disease
Georg Thieme Verlag KG Stuttgart · New York

Cangrelor versus Ticagrelor in Patients Treated with Primary Percutaneous Coronary Intervention: Impact on Platelet Activity, Myocardial Microvascular Function and Infarct Size: A Randomized Controlled Trial

Salahaddin Ubaid
1   Heart and Lung Centre, New Cross Hospital, Wolverhampton, United Kingdom
,
Thomas J. Ford
2   Golden Jubilee National Hospital, Glasgow, United Kingdom
3   British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom
,
Colin Berry
2   Golden Jubilee National Hospital, Glasgow, United Kingdom
3   British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom
,
Heather M. Murray
4   Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom
,
Benjamin Wrigley
1   Heart and Lung Centre, New Cross Hospital, Wolverhampton, United Kingdom
,
Nazish Khan
1   Heart and Lung Centre, New Cross Hospital, Wolverhampton, United Kingdom
,
Mark R. Thomas
5   Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
,
Angel L. Armesilla
6   School of Pharmacy, University of Wolverhampton, Wolverhampton, United Kingdom
,
Jon N. Townend
7   Queen Elizabeth Hospital, Birmingham, United Kingdom
,
Saib S. Khogali
1   Heart and Lung Centre, New Cross Hospital, Wolverhampton, United Kingdom
,
Shahzad Munir
1   Heart and Lung Centre, New Cross Hospital, Wolverhampton, United Kingdom
,
Joe Martins
1   Heart and Lung Centre, New Cross Hospital, Wolverhampton, United Kingdom
,
Sandeep S. Hothi
1   Heart and Lung Centre, New Cross Hospital, Wolverhampton, United Kingdom
,
Elisa J. McAlindon
1   Heart and Lung Centre, New Cross Hospital, Wolverhampton, United Kingdom
,
James M. Cotton
1   Heart and Lung Centre, New Cross Hospital, Wolverhampton, United Kingdom
6   School of Pharmacy, University of Wolverhampton, Wolverhampton, United Kingdom
› Author Affiliations Funding This work was supported by the South Staffordshire Medical Foundation, the Rotha Abraham Bequest and the Royal Wolverhampton Trust (RE/2015005). This study was sponsored by the Royal Wolverhampton NHS Trust. C.B. and T.F. received funding support from the British Heart Foundation (PG/17/2532884; RE/13/5/30177; RE/18/6134217).
Further Information

Publication History

22 January 2019

23 March 2019

Publication Date:
26 May 2019 (online)

    Permissions and Reprints

Abstract

Background Oral P2Y12 inhibitors take more than 2 hours to achieve full effect in healthy subjects and this action is further delayed in patients with acute myocardial infarction. Intravenous P2Y12 inhibition might lead to more timely and potent anti-platelet effect in the context of emergency primary angioplasty, improving myocardial recovery.

Objectives This article compares the efficacy of intravenous cangrelor versus ticagrelor in a ST-elevation myocardial infarction (STEMI) population treated with primary percutaneous coronary intervention (PPCI).

Materials and Methods In an open-label, prospective, randomized controlled trial, 100 subjects with STEMI were assigned 1:1 to intravenous cangrelor or oral ticagrelor. The co-primary endpoints were platelet P2Y12 inhibition at infarct vessel balloon inflation time, 4 and 24 hours. Secondary endpoints included indices of coronary microcirculatory function: index of microvascular resistance (IMR), initial infarct size (troponin at 24 hours) and final infarct size at 12 weeks (cardiac magnetic resonance). Secondary endpoints included indices of coronary microcirculatory function (index of microvascular resistance [IMR]), initial infarct size (troponin at 24 hours), final infarct size at 12 weeks (cardiac magnetic resonance), corrected thrombolysis in myocardial infarction (TIMI) frame count, TIMI flow grade, myocardial perfusion grade, and ST-segment resolution (ClinicalTrials.gov NCT02733341).

Results P2Y12 inhibition at first balloon inflation time was significantly greater in cangrelor-treated patients (cangrelor P2Y12 reaction unit [PRU] 145.2 ± 50.6 vs. ticagrelor 248.3 ± 55.1). There was no difference in mean PRU at 4 and 24 to 36 hours post-dosing. IMR, final infarct size, angiographic and electrocardiographic measures of reperfusion were all similar between groups.

Conclusion Cangrelor produces more potent P2Y12 inhibition at the time of first coronary balloon inflation time compared with ticagrelor. Despite this enhanced P2Y12 inhibition, coronary microvascular function and final infarct size did not differ between groups.

Keywords

anti-platelet - infarct size - microcirculation - myocardial infarction - percutaneous coronary intervention
 

  • References

  • 1 Ibanez B, James S, Agewall S. , et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39 (02) 119-177
    CrossrefPubMedGoogle Scholar
  • 2 Sibbing D, Kastrati A, Berger PB. Pre-treatment with P2Y12 inhibitors in ACS patients: who, when, why, and which agent?. Eur Heart J 2016; 37 (16) 1284-1295
    CrossrefPubMedGoogle Scholar
  • 3 Franchi F, Rollini F, Angiolillo DJ. Antithrombotic therapy for patients with STEMI undergoing primary PCI. Nat Rev Cardiol 2017; 14 (06) 361-379
    CrossrefPubMedGoogle Scholar
  • 4 Alexopoulos D, Pappas C, Sfantou D. , et al. Cangrelor in ticagrelor-loaded STEMI patients undergoing primary percutaneous coronary intervention. J Am Coll Cardiol 2018; 72 (14) 1750-1751
    CrossrefPubMedGoogle Scholar
  • 5 Franchi F, Rollini F, Rivas A. , et al. Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the CANTIC Study. Circulation 2019; 139 (14) 1661-1670
    CrossrefPubMedGoogle Scholar
  • 6 Capodanno D, Angiolillo DJ. Antiplatelet therapy after implantation of bioresorbable vascular scaffolds: a review of the published data, practical recommendations, and future directions. JACC Cardiovasc Interv 2017; 10 (05) 425-437
    CrossrefPubMedGoogle Scholar
  • 7 Carrick D, Haig C, Ahmed N. , et al. Comparative prognostic utility of indexes of microvascular function alone or in combination in patients with an acute ST-segment-elevation myocardial infarction. Circulation 2016; 134 (23) 1833-1847
    CrossrefPubMedGoogle Scholar
  • 8 Brener SJ, Maehara A, Dizon JM. , et al. Relationship between myocardial reperfusion, infarct size, and mortality: the INFUSE-AMI (Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction) trial. JACC Cardiovasc Interv 2013; 6 (07) 718-724
    CrossrefPubMedGoogle Scholar
  • 9 Morishima I, Sone T, Okumura K. , et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000; 36 (04) 1202-1209
    CrossrefPubMedGoogle Scholar
  • 10 Porto I, Biasucci LM, De Maria GL. , et al. Intracoronary microparticles and microvascular obstruction in patients with ST elevation myocardial infarction undergoing primary percutaneous intervention. Eur Heart J 2012; 33 (23) 2928-2938
    CrossrefPubMedGoogle Scholar
  • 11 Price MJ, Angiolillo DJ, Teirstein PS. , et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 2011; 124 (10) 1132-1137
    CrossrefPubMedGoogle Scholar
  • 12 Fearon WF, Balsam LB, Farouque HM. , et al. Novel index for invasively assessing the coronary microcirculation. Circulation 2003; 107 (25) 3129-3132
    CrossrefPubMedGoogle Scholar
  • 13 Gupta A, Taqueti VR, van de Hoef TP. , et al. Integrated noninvasive physiological assessment of coronary circulatory function and impact on cardiovascular mortality in patients with stable coronary artery disease. Circulation 2017; 136 (24) 2325-2336
    CrossrefPubMedGoogle Scholar
  • 14 Appleby MA, Michaels AD, Chen M, Michael CG. Importance of the TIMI frame count: implications for future trials. Curr Control Trials Cardiovasc Med 2000; 1 (01) 31-34
    CrossrefPubMedGoogle Scholar
  • 15 de Lemos JA, Braunwald E. ST segment resolution as a tool for assessing the efficacy of reperfusion therapy. J Am Coll Cardiol 2001; 38 (05) 1283-1294
    CrossrefPubMedGoogle Scholar
  • 16 McAlindon E, Pufulete M, Lawton C, Angelini GD, Bucciarelli-Ducci C. Quantification of infarct size and myocardium at risk: evaluation of different techniques and its implications. Eur Heart J Cardiovasc Imaging 2015; 16 (07) 738-746
    CrossrefPubMedGoogle Scholar
  • 17 Mehran R, Rao SV, Bhatt DL. , et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123 (23) 2736-2747
    CrossrefPubMedGoogle Scholar
  • 18 Hochholzer W, Kleiner P, Younas I. , et al. Randomized comparison of oral P2Y12-receptor inhibitor loading strategies for transitioning from cangrelor: the ExcelsiorLOAD2 Trial. JACC Cardiovasc Interv 2017; 10 (02) 121-129
    CrossrefPubMedGoogle Scholar
  • 19 Frossard M, Fuchs I, Leitner JM. , et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 2004; 110 (11) 1392-1397
    CrossrefPubMedGoogle Scholar
  • 20 Campo G, Valgimigli M, Gemmati D. , et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study. J Am Coll Cardiol 2006; 48 (11) 2178-2185
    CrossrefPubMedGoogle Scholar
  • 21 Velders MA, Abtan J, Angiolillo DJ. , et al; PLATO Investigators. Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. Heart 2016; 102 (08) 617-625
    CrossrefPubMedGoogle Scholar
  • 22 Kunadian V, James SK, Wojdyla DM. , et al. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). JACC Cardiovasc Interv 2013; 6 (07) 671-683
    CrossrefPubMedGoogle Scholar
  • 23 Montalescot G, van 't Hof AW, Lapostolle F. , et al; ATLANTIC Investigators. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 2014; 371 (11) 1016-1027
    CrossrefPubMedGoogle Scholar
  • 24 Alexopoulos D, Gkizas V, Patsilinakos S. , et al. Double versus standard loading dose of ticagrelor: onset of antiplatelet action in patients with STEMI undergoing primary PCI. J Am Coll Cardiol 2013; 62 (10) 940-941
    CrossrefPubMedGoogle Scholar
  • 25 Alexopoulos D, Barampoutis N, Gkizas V. , et al. Crushed versus integral tablets of ticagrelor in ST-segment elevation myocardial infarction patients: a randomized pharmacokinetic/pharmacodynamic study. Clin Pharmacokinet 2016; 55 (03) 359-367
    CrossrefPubMedGoogle Scholar
  • 26 Steg PG, Bhatt DL, Hamm CW. , et al; CHAMPION Investigators. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 2013; 382 (9909): 1981-1992
    CrossrefPubMedGoogle Scholar
  • 27 Costantini CO, Stone GW, Mehran R. , et al. Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. J Am Coll Cardiol 2004; 44 (02) 305-312
    CrossrefPubMedGoogle Scholar